Nantahala Capital Management LLC Buys Shares of 5,894,114 TELA Bio, Inc. $TELA

Nantahala Capital Management LLC acquired a new stake in shares of TELA Bio, Inc. (NASDAQ:TELA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,894,114 shares of the company’s stock, valued at approximately $4,420,586. Nantahala Capital Management LLC owned about 0.13% of TELA Bio at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Essex Woodlands Management Inc. raised its position in TELA Bio by 87.7% during the fourth quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock valued at $9,103,000 after acquiring an additional 3,604,000 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in TELA Bio in the second quarter worth approximately $1,996,820. Perkins Capital Management Inc. grew its position in TELA Bio by 1.5% in the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock worth $879,000 after acquiring an additional 20,910 shares in the last quarter. BlackRock Inc. acquired a new position in shares of TELA Bio during the 2nd quarter worth $281,000. Finally, WealthTrust Axiom LLC increased its stake in shares of TELA Bio by 39.1% during the 4th quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after purchasing an additional 90,650 shares during the last quarter. Hedge funds and other institutional investors own 94.35% of the company’s stock.

TELA Bio Stock Up 7.7%

Shares of TELA stock opened at $0.70 on Friday. TELA Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.87. The firm has a market cap of $31.43 million, a PE ratio of -0.91 and a beta of 1.34. The stock has a 50 day moving average of $0.74 and a 200-day moving average of $0.78. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82.

TELA Bio (NASDAQ:TELA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%.The company had revenue of $19.29 million during the quarter, compared to analyst estimates of $20.01 million. On average, equities analysts predict that TELA Bio, Inc. will post -0.76 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.20.

TELA Bio Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.